6月23日，晶泰控股盘中上涨5.05%，报7.07港元/股，成交额4.59亿港元。
消息面上，国家药监局6月22日发布2025年《中国新药注册临床试验进展年度报告》，我国临床试验总量首次突破5000项创历史新高，新药临床试验2997项，同比增长18%。叠加《利用外资固稳促优行动方案》支持外资参与医药产业发展，创新药板块集体走强。晶泰控股作为AI驱动药物研发平台，近期刚主办AI驱动新药研发创新峰会，披露全闭环研发体系及最新临床进展，板块情绪共振下资金回流明显。同行业中，英矽智能涨7.9%，药明合联涨1.45%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.